Novo Nordisk reported DKK17.1B in Cost of Sales for its fiscal quarter ending in June of 2026.





Cost Of Sales Change Date
Bausch Health Companies USD 997M 18M Jun/2026
Bristol-Myers Squibb USD 7.89B 4.03B Jun/2026
Eli Lilly USD 3.27B 309M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Merck USD 3.14B 200M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Novo Nordisk DKK 17.1B 3.5B Jun/2026
Novo Nordisk DKK 2.66B 10.94B Jun/2026
Pacira USD 58.49M 7.75M Jun/2026
Sanofi EUR 3.02B 656M Jun/2026
Supernus Pharmaceuticals USD 59M 9.97M Jun/2026